(New York, Shanghai) – February 13, 2015 – the world's leading cloud solutions provider in the field of life science clinical research Medidata (NASDAQ: MDSO) announced today that Cheng bio-tech company limited (Twi Biotechnology, Inc.) decided to adopt the company's industry-leading technology platform. As Taiwan a leading biopharmaceutical company, Cheng Medidata Clinical Cloud ® to enhance biotechnology metabolic disease clinical studies carried out by the company's new speed, quality and efficiency.
Previous: China's Largest Latent TB Infection In Pivotal Clinical Trials
Next: No Information